DDInter1925 DDInter1491
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Vemurafenib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Vemurafenib {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Pomalidomide
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Vemurafenib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Vemurafenib {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Vemurafenib {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) binds {v} (Gene) TNF
TNF {u} (Gene) is bound by {v} (Compound) Pomalidomide
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Pomalidomide
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)
Vemurafenib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pomalidomide (Compound)
Vemurafenib (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pomalidomide (Compound)
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Vemurafenib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Thalidomide (Compound) and Thalidomide (Compound) resembles Pomalidomide (Compound)
Vemurafenib (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Vemurafenib (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) binds TNF (Gene) and TNF (Gene) is bound by Pomalidomide (Compound)
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pomalidomide (Compound)
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)